AB Science SA (Euronext - FR0010557264 - AB) today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Symptoms come and go in most cases of multiple sclerosis (MS), a chronic disease in which the immune system attacks myelin, the nonconductive sheath that surrounds neurons' axons. Yet 10 to 15 percent ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS® (ocrelizumab) in people with relapsing and ...

EXTON, Pa., June 26, 2018 /PRNewswire/ -- Largely fueled by Genentech's Ocrevus availability, a paradigm shift has occurred in the US multiple sclerosis (MS) market resulting in increased rates of ...

AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...